Cangrelor sodium (ARC69931MX; AR-C69931; Kengreal, CANREAL; Kengrexal), the tetra-sodium salt of cangrelor which is an ATP analog, is a reversible, selective and direct-acting P2Y12 inhibitor approved in June 2015 as an antiplatelet drug for intravenous application.

BPTU (BMS-646786), a non-nucleotide structure, is a new P2Y1 antagonist which has recently been described using X-ray crystallography as the first allosteric G-protein-coupled receptor antagonist located entirely outside of the helical bundle.

Diquafosol tetrasodium (Diquas; INS-365) is a novel and potent P2Y2 purinoceptor agonist that stimulates fluid and mucin secretion on the ocular surface, and is used as a topical treatment of dry eye disease.

Vicagrel is the acetated form of Clopidogrel with antithrombotic activity.

2MeSADP is a novel and potent purinergic agonist which acts by displaying selectivity for P2Y1, P2Y12 and P2Y13 receptors and inhibiting cAMP accumulation.

AZD1283 is a novel, potent and selective antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10 and with binding IC50 of 11 nM.

Clopidogrel thiolactone (also known as 2-Oxoclopidogrel) is a metabolite of Clopidogrel which is a P2Y12 receptor inhibitor.

Prasugrel Hydrochloride (formerly also known as CS-747, PCR 4099 and LY640315), a piperazine derivative, is a novel and potent thienopyridine ADP receptor (P2Y12) antagonist used for the reduction of thrombotic cardiovascular events.